Overview

Study to Assess the Effects of Angiopoietin-like Protein 3 (ANGPTL3) Inhibition in Adult Participants With Diabetic Kidney Disease

Status:
NOT_YET_RECRUITING

Trial end date:
2027-12-08

Target enrollment:

Participant gender:

Summary

This study is researching experimental drugs called ALN-ANG3 and evinacumab (called "study drugs"). The study is focused on participants who have diabetic kidney disease. The aim of the study is to see how safe and effective the study drugs are. The study is looking at several other research questions, including: * What side effects may happen from taking the study drug * How much study drug is in the blood at different times

Phase:

PHASE2

Details

Lead Sponsor:

Regeneron Pharmaceuticals

Treatments:

evinacumab